Etoposide

Retinoblastoma, Testicular Neoplasms, Sarcoma + 17 more

Treatment

4 FDA approvals

20 Active Studies for Etoposide

What is Etoposide

Etoposide

The Generic name of this drug

Treatment Summary

Etoposide is a drug that stops the growth of cancer cells. It works by targeting topoisomerase II, an enzyme that helps with the process of DNA replication. When Etoposide binds to the enzyme and DNA, it prevents the repair of breaks in the DNA strands, which prevents the cancer cells from entering the cell division phase. Etoposide is most effective in the G2 and S phases of the cell cycle.

VePesid

is the brand name

image of different drug pills on a surface

Etoposide Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

VePesid

Etoposide

1983

31

Approved as Treatment by the FDA

Etoposide, also known as VePesid, is approved by the FDA for 4 uses which include Non-Small Cell Lung Cancer and Non-Small Cell Lung Carcinoma (NSCLC) .

Non-Small Cell Lung Cancer

Used to treat Non-Small Cell Lung Carcinoma (NSCLC) in combination with null

Non-Small Cell Lung Carcinoma (NSCLC)

Used to treat Non-Small Cell Lung Carcinoma (NSCLC) in combination with null

Non-Hodgkin's Lymphoma (NHL)

Used to treat Non-Hodgkin's Lymphoma (NHL) in combination with null

Non-Hodgkin's Lymphoma

Used to treat Non-Hodgkin's Lymphoma (NHL) in combination with null

Effectiveness

How Etoposide Affects Patients

Etoposide is a medicine used to treat cancer. It works by stopping the growth and replication of cancer cells, especially cells in the S and G2 stages of the cellular cycle. At higher doses, it can destroy cells entering mitosis. At lower doses, it inhibits cells from entering prophase. It does not mess with the assembly of microtubules. Etoposide interacts with DNA topoisomerase II or forms free radicals which breaks the DNA strands of cancer cells.

How Etoposide works in the body

Etoposide stops DNA from forming properly in cancer cells. This causes errors during cell division and leads these cells to die. Etoposide works specifically on the S and G2 phases of cell division, and targets a certain enzyme (topoisomerase II alpha isoform) to cause this disruption. It can also affect another enzyme (topoisomerase II beta isoform), but this is not associated with anti-tumor activity and instead can cause cancer cells to form instead.

When to interrupt dosage

The measure of Etoposide is contingent upon the diagnosed state, including Gestational Trophoblastic Disease, recalcitrant Testicular cancer and Retinoblastoma. The volume of dosage deviates as per the method of delivery (e.g. Capsule - Oral or Capsule, liquid filled - Oral) featured in the table below.

Condition

Dosage

Administration

Retinoblastoma

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Testicular Neoplasms

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Sarcoma

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Carcinoma, Merkel Cell

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Neoplasms

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Advance Directives

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Sarcoma

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Ovarian Cancer

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Non-Small Cell Lung Cancer

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Thymus Neoplasms

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Multiple Myeloma

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Neuroblastoma

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Acute Myeloid Leukemia

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Non-Hodgkin's Lymphoma

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Acute Lymphoblastic Leukemia

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Sarcoma

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Small Cell Lung Cancer

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Gestational Trophoblastic Disease

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Prostate Cancer

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Hodgkin Disease

, 20.0 mg/mL, 50.0 mg, 100.0 mg, 50.0 mg/mL, 100.0 mg/mL, 150.0 mg/mL

Injection, solution, concentrate, , Intravenous, Injection, solution, concentrate - Intravenous, Injection - Intravenous, Injection, Liquid, Liquid - Intravenous, Oral, Capsule - Oral, Capsule, Solution, Solution - Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule, liquid filled, Capsule, liquid filled - Oral

Warnings

There are 20 known major drug interactions with Etoposide.

Common Etoposide Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Etoposide is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Etoposide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Etoposide is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Etoposide is combined with Acteoside.

Aldosterone

Major

The risk or severity of adverse effects can be increased when Etoposide is combined with Aldosterone.

Etoposide Toxicity & Overdose Risk

Taking too much of this drug can cause hair loss, constipation, diarrhea, nausea or vomiting, and an increased risk of developing cancer such as leukemia.

image of a doctor in a lab doing drug, clinical research

Etoposide Novel Uses: Which Conditions Have a Clinical Trial Featuring Etoposide?

1617 active studies are examining the potential of Etoposide to combat Neuroblastoma (NB), Merkel cell cancer and Non-Small Cell Lung Cancer.

Condition

Clinical Trials

Trial Phases

Acute Myeloid Leukemia

267 Actively Recruiting

Phase 2, Phase 3, Phase 1, Phase 4, Not Applicable, Early Phase 1

Ovarian Cancer

13 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3

Small Cell Lung Cancer

50 Actively Recruiting

Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1

Sarcoma

1 Actively Recruiting

Phase 2

Advance Directives

0 Actively Recruiting

Neuroblastoma

0 Actively Recruiting

Sarcoma

0 Actively Recruiting

Retinoblastoma

5 Actively Recruiting

Phase 2, Phase 1

Testicular Neoplasms

0 Actively Recruiting

Carcinoma, Merkel Cell

0 Actively Recruiting

Hodgkin Disease

0 Actively Recruiting

Gestational Trophoblastic Disease

1 Actively Recruiting

Phase 2

Multiple Myeloma

6 Actively Recruiting

Phase 1, Phase 2

Thymus Neoplasms

1 Actively Recruiting

Phase 1

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Neoplasms

0 Actively Recruiting

Prostate Cancer

68 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Non-Small Cell Lung Cancer

358 Actively Recruiting

Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4, Early Phase 1

Sarcoma

0 Actively Recruiting

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Etoposide Reviews: What are patients saying about Etoposide?

3.7

Patient Review

2/2/2010

Etoposide for Ovarian Germ Cell Cancer

After just one series, my CA-125 (a marker for ovarian cancer) went down 1000 points. I'm now on my second series and feeling more hopeful every day.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about etoposide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of chemo is etoposide?

"Etoposide is a medication that belongs to a class of drugs known as podophyllotoxin derivatives. These drugs work by slowing or stopping the growth of cancer cells in the body."

Answered by AI

What cancers is etoposide used for?

"Etoposide is used to treat testicular, bladder, prostate, lung, stomach, and uterine cancers, Hodgkin's and non-Hodgkin's lymphoma, mycosis fungoides, Kaposi's sarcoma, Wilm's tumor, rhabdomyosarcoma, Ewing's sarcoma, neuroblastoma, and brain tumors."

Answered by AI

What is the mechanism of action of etoposide?

"Etoposide prevents DNA synthesis by creating a bond between topoisomerase II and DNA. This bond interferes with the ability of topoisomerase II to bind to DNA, which prevents DNA from being repaired. Over time, this accumulates breaks in DNA, which eventually prevents cells from entering the mitotic phase of cell division, causing the cells to die."

Answered by AI

What are the side effects of the drug etoposide?

"If you experience any of the following side effects, call your doctor immediately or get emergency medical help:

Possible side effects include feeling sick (nausea), being sick (vomiting), diarrhoea, feeling dizzy or tired, weakness, changes in your sense of taste, loss of appetite, and pain or redness around the site of the injection. These side effects can sometimes be severe. If you have any of these side effects, do not delay seeking medical attention."

Answered by AI

Clinical Trials for Etoposide

Image of Massachusetts General Hospital in Boston, United States.

Ivonescimab + Chemotherapy for NSCLC

18+
All Sexes
Boston, MA

The goal of this clinical trial is to assess the efficacy of ivonescimab monotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations who have received prior targeted therapies and chemotherapy. This clinical trial also aims to assess the efficacy of ivonescimab plus carboplatin/pemetrexed chemotherapy in patients with advanced non-small cell lung cancer harboring actionable genomic alterations other than epidermal growth factor receptor mutations who have received prior targeted therapies but no chemotherapy. The main questions it aims to answer are: * Will ivonescimab alone or together with carboplatin/pemetrexed chemotherapy shrink tumors in the clinical trial's patients? * Will ivonescimab alone or together with carboplatin/pemetrexed chemotherapy effectively influence if the patients' cancer grows, how long the treatment takes to start working, how long the treatment keeps working after it first starts to help, how long the treatment keeps the cancer from getting worse, and overall survival of patients? * How many patients receiving ivonescimab alone or together with carboplatin/pemetrexed chemotherapy will experience treatment-emergent, treatment-related, immune-related, and especially interesting side effects? Patients receiving ivonescimab alone will receive an intravenous infusion of ivonescimab every 3 weeks for up to 24 months. Patients receiving ivonescimab together with carboplatin/pemetrexed chemotherapy will receive separate intravenous infusions of ivonescimab, pemetrexed, and carboplatin every 3 weeks for 4 cycles (each cycle is 21 days). These patients will continue to receive infusions of ivonescimab and pemetrexed every 3 weeks for up to 24 total months.

Phase 2
Waitlist Available

Massachusetts General Hospital (+2 Sites)

Jessics J Lin, MD

Summit Therapeutics

Have you considered Etoposide clinical trials?

We made a collection of clinical trials featuring Etoposide, we think they might fit your search criteria.
Go to Trials
Image of Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) in Basking Ridge, United States.

Ivosidenib + Azacitidine + Venetoclax for Acute Myeloid Leukemia

18+
All Sexes
Basking Ridge, NJ

The researchers are doing this study to find out whether a 3-drug combination of ivosidenib, azacitidine, and venetoclax followed by maintenance therapy with ivosidenib alone is an effective treatment approach for people with newly diagnosed acute myeloid leukemia (AML) that has an IDH mutation. Maintenance therapy is additional treatment given to help keep cancer from coming back after it has disappeared following the first course of treatment. The researchers will also look at the safety of the treatment approach and what kind of a time commitment it involves for participants.

Phase 2
Recruiting

Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) (+6 Sites)

Kuo-Kai Chin, MD

Image of M D Anderson Cancer Center in Houston, United States.

Decision Support Tool for Prostate Cancer

18+
Male
Houston, TX

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

Waitlist Available
Has No Placebo

M D Anderson Cancer Center

Debanjan Pain

Image of Beth Israel Deaconess Medical Center in Boston, United States.

T-Cell Therapy + Vaccine + Drugs for Acute Myeloid Leukemia

Any Age
All Sexes
Boston, MA

The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and venetoclax is feasible and safe and effective for treatment of acute myeloid leukemia (AML). The names of the study drugs involved in this study are: * DC/AML fusion vaccine (immune cell vaccine) * Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone) * DC/AML Primed T cells (immune cells) * Decitabine (a type of chemotherapy drug) * Venetoclax (a type of antineoplastic agent)

Phase 1
Waitlist Available

Beth Israel Deaconess Medical Center

David Avigan, MD

Have you considered Etoposide clinical trials?

We made a collection of clinical trials featuring Etoposide, we think they might fit your search criteria.
Go to Trials
Image of Henry Ford Cancer- Detroit in Detroit, United States.

SG + Immunotherapy for Lung Cancer

18+
All Sexes
Detroit, MI

The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination. The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors. Participants in the trial will: * receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient. * CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks. * provide tissue (optional) and blood for additional testing (learn about the cancer).

Phase 2
Recruiting

Henry Ford Cancer- Detroit

Gilead Sciences

Image of National Institutes of Health Clinical Center in Bethesda, United States.

CD22 CAR T-cells for Acute Lymphoblastic Leukemia

3 - 65
All Sexes
Bethesda, MD

Background: Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Chimeric antigen receptor (CAR) therapy involves taking immune cells (T cells) from a person and modifying them to better target cancer cells. CAR T-cell therapy that targets a marker called CD19 has been show to can cure ALL in many children and adults. But in about 50% of patients, the ALL comes back within a year. Researchers want to find out if a second treatment with CAR T-cell therapy that targets a different marker, CD22, can keep the cancer away longer. Objective: To see if CD22 CAR T-cell therapy can keep ALL away longer. Eligibility: People aged 3 to 65 years who have no signs of cancer after CD19 CAR T-cell treatment for ALL. Design: Participants will be screened. They will have imaging scans and tests of their heart function. A sample of tissue (biopsy) will be collected from their bone marrow. They will have a fluid sample collected from the area around their spinal cord. Participants will undergo collection of their white blood cells (T cells) during a procedure called leukapheresis. Blood will be taken from their body through a vein. The blood will pass through a machine that separates out the T cells. The remaining blood will be returned to the body through a different vein. The cells will be altered in a lab to create CD22 CAR T-cell therapy. Participants will take drugs over 4 consecutive days to prepare their body for the CAR T-cell therapy; then they will receive their modified T cells through a tube inserted into a vein. Some people may need to stay in the hospital during treatment. Participants will have follow-up visits for 2 years.

Phase 2
Waitlist Available

National Institutes of Health Clinical Center

Sara K Silbert, M.D.

Have you considered Etoposide clinical trials?

We made a collection of clinical trials featuring Etoposide, we think they might fit your search criteria.
Go to Trials